The overarching aim is to identify metabolites that predict kidney cell phenotypes during chronic kidney disease, and investigate how crosstalk between metabolites and the proteome worsens the disease.

Chronic kidney disease, a progressive disease that can eventually lead to kidney failure, is also associated to increased risk of cardiovascular disease. As such, chronic kidney disease remains a major global health and socioeconomic burden. Chronic kidney disease increases cardiovascular morbidity and premature mortality and it decreases patients’ quality of life. Although approximately 1 in 4 people will develop chronic kidney disease during their lifetime, research activity in this area has only recently gained momentum. Thus, there is an urgent need for new approaches for early identification of the individuals most “at risk” and to identify signatures of the disease to aid in designing novel drugs and preventive measures.

Participants:

• Professor Robert Fenton, Department of Biomedicine
• Associate Professor Markus Rinschen, Department of Biomedicine
• Associate Professor Ken Howard, iNANO/Department of Molecular Biology and Genetics
• Professor Ira Assent, Department of Computer Science
• Professor Pernille Lærkegaard Hansen, AstraZeneca AB
• Anna Björnson Granqvist, AstraZeneca AB